- Home
- NRO vs GNLX Comparison
NRO vs GNLX Comparison
Compare NRO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- GNLX
- Stock Information
- Founded
- NRO 2003
- GNLX 2001
- Country
- NRO United States
- GNLX United States
- Employees
- NRO N/A
- GNLX N/A
- Industry
- NRO Finance/Investors Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- GNLX Health Care
- Exchange
- NRO Nasdaq
- GNLX Nasdaq
- Market Cap
- NRO 156.7M
- GNLX 128.0M
- IPO Year
- NRO N/A
- GNLX 2023
- Fundamental
- Price
- NRO $3.28
- GNLX $3.40
- Analyst Decision
- NRO
- GNLX Strong Buy
- Analyst Count
- NRO 0
- GNLX 4
- Target Price
- NRO N/A
- GNLX $17.75
- AVG Volume (30 Days)
- NRO 239.4K
- GNLX 109.1K
- Earning Date
- NRO 01-01-0001
- GNLX 08-07-2025
- Dividend Yield
- NRO 11.41%
- GNLX N/A
- EPS Growth
- NRO N/A
- GNLX N/A
- EPS
- NRO N/A
- GNLX N/A
- Revenue
- NRO N/A
- GNLX N/A
- Revenue This Year
- NRO N/A
- GNLX N/A
- Revenue Next Year
- NRO N/A
- GNLX N/A
- P/E Ratio
- NRO N/A
- GNLX N/A
- Revenue Growth
- NRO N/A
- GNLX N/A
- 52 Week Low
- NRO $2.51
- GNLX $1.95
- 52 Week High
- NRO $3.45
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- NRO 54.65
- GNLX 49.00
- Support Level
- NRO $3.20
- GNLX $3.26
- Resistance Level
- NRO $3.34
- GNLX $3.61
- Average True Range (ATR)
- NRO 0.04
- GNLX 0.22
- MACD
- NRO 0.00
- GNLX -0.03
- Stochastic Oscillator
- NRO 50.00
- GNLX 17.28
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.